Viral Vector Capabilities

AGC Biologics scientists have three decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products.

Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house.

Our quality systems, manufacturing scales, and regulatory expertise allow us to meet both clinical and commercial viral vector demands. Moreover, our scale-down capabilities provide flexible and cost-effective solutions for process development and pre-clinical studies.

Viral Vectors Production and Manufacturing Services

• Viral Vectors services including development, characterization, and manufacturing (PD/cGMP environment)
• Small, medium, and large-scale equipment for both adhesion and suspension-based processes
• A reliable and flexible platform for various scales of AAV production with different serotypes
• Plug-and-play platform for large-scale AAV and LVV manufacturing that can be adapted to virtually any program
• cGMP viral vector manufacturing at various scales up to 2,000L across two global sites
• iCELLis 500 bioreactor technology used for adherent processes up to 200L, and for scale-up of adhesion-based processes
• 160+ in-house analytical tests with custom designs for clinical and commercial supply
• Quality systems and teams of scientists with 30 years of global regulatory experience in the cell and gene field